The APE1 Asp/Asp Genotype and the Combination of APE1 Asp/Asp and hOGG1-Cys Variants Are Associated With Increased p53 Mutation in Non–Small Cell Lung Cancer

Chun-Hsuan Lin¹, Po-Ming Chen², Ya-Wen Cheng³, Chih-Yi Chen⁴, Chiun-Jye Yuan¹, and Huei Lee³

¹Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan, ROC
²Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
³Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan, ROC
⁴Department of Surgery, China Medical University Hospital, Taichung, Taiwan, ROC

Received March 16, 2012; accepted June 27, 2012; released online September 29, 2012

ABSTRACT

Background: The hOGG1 Ser326Cys polymorphism is associated with lung cancer risk, but there are limited data regarding an association between the APE1 Asp148Glu polymorphism and lung cancer. Biological evidence shows that the hOGG1-Cys allele results in less DNA repair activity; however, this is not associated with p53 mutation in lung cancer. Therefore, we investigated whether an interaction between hOGG1 and APE1 is associated with the frequency of p53 mutation in lung cancer.

Methods: We studied 217 Taiwanese adults with primary lung cancer. DNA polymorphisms of hOGG1 and APE1 were determined by polymerase chain reaction (PCR)-based restriction fragment length polymorphism. Mutations in p53 exons 5–8 were detected by direct sequencing. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% CIs for the risk of p53 mutation associated with polymorphisms of hOGG1 and APE1 in lung cancer.

Results: As expected, no association between hOGG1 polymorphism and p53 mutation was observed in this population. However, a higher risk of p53 mutation was found in participants with the APE1 Asp/Asp genotype than in those with the APE1-Glu allele (OR, 2.15; 95% CI, 1.19–3.87; P = 0.011). The risk of p53 mutation was also higher in participants with APE1 Asp/Asp plus hOGG1-Cys than in those with APE1-Glu plus hOGG1 Ser/Ser (OR, 3.72; 95% CI, 1.33–10.40; P = 0.012).

Conclusions: These results suggest that the APE1 Asp/Asp genotype and the combination of the APE1 Asp/Asp and hOGG1-Cys variants are associated with increased risk of p53 mutation in non–small cell lung cancer.

Key words: hOGG1 Ser326Cys; APE1 Asp148Glu; p53 mutation; NSCLC

INTRODUCTION

In Taiwan, lung cancer is the leading cause of cancer death among women and the second leading cause among men.¹ Cigarette smoking is considered to be the primary cause of lung cancer; however, less than 20% of smokers develop lung cancer.²,³ Thus, it is possible that different individuals have different capacities for detoxification and DNA repair. Exposure to tobacco smoke might induce oxidative DNA damage that, when combined with impaired DNA repair, may increase lung cancer risk.⁴-⁷ Reactive oxygen species (ROS) are linked to chronic inflammation and lung cancer development.⁸,⁹ Oxidative reactions due to ROS give rise to DNA modifications, which are then primarily repaired via a DNA base excision repair pathway. DNA repair is initiated by excision of damaged bases by specific DNA glycosylases, such as human 8-oxoguanine-DNA glycosylase (hOGG1) and apurinic/apyrimidinic endonuclease 1 (APE1).¹⁰-¹² Research has shown that the product of the Ser326 allele of hOGG1 has an increased capacity for removing 8-hydroxyguanin and a high binding affinity for DNA.¹³,¹⁴ In contrast, a biochemical assay showed that the product of the APE1 Asp148Glu allele had similar endonuclease and DNA binding activity to the wild-type allele.¹⁵ The association of the base excision repair genes hOGG1 and APE1 with lung cancer risk had been extensively investigated. Most of these studies were case-control studies...
that found an association between hOGG1 Ser326Cys polymorphism and increased lung cancer risk\textsuperscript{16–20}, however, most found no association between APE1 Asp148Glu polymorphism and lung cancer risk.\textsuperscript{16,21–23} The exception was 1 report that showed that APE1 Asp148Glu polymorphism was associated with lung cancer risk after adjusting for age, sex, and smoking.\textsuperscript{24} Interestingly, the hOGG1 and APE1 genetic polymorphisms were significantly associated with lung cancer risk in heavy smokers but not in light smokers or nonsmokers.\textsuperscript{16–22}

p53 mutation, which is induced by carcinogens in cigarette smoke, frequently occurs in exons 5–8. This is the principal known carcinogenic pathway involved in lung cancer among smokers.\textsuperscript{25,26} At this time, there is no molecular evidence to indicate any similar association of hOGG1 Ser326Cys or APE1 Asp148Glu with lung cancer risk.

In the present study, we obtained tissue samples from lung tumors and adjacent normal lung from 217 Taiwanese patients with lung cancer. We examined p53 mutation in lung tumors by direct sequencing and used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to determine the existing genetic polymorphisms of hOGG1 and APE1 in the normal lung tissue. Genotyping analysis of both genes was confirmed in control subjects ($n = 206$) and accorded with the Hardy–Weinberg equilibrium (eTable 1). The aim of this study was to determine whether the hOGG1 Ser326Cys and APE1 Asp148Glu genetic polymorphisms were associated with increased p53 mutation in lung cancer.

**RESULTS**

**Association of hOGG1 Ser326Cys and APE1 Asp148Glu with p53 mutation in lung cancer**

PCR-RFLP analysis was used to examine the hOGG1 Ser326Cys and APE1 Asp148Glu polymorphisms. The association of the hOGG1 and APE1 polymorphisms with clinicopathologic parameters in Taiwanese with lung cancer is shown in Table 1. No association with clinical parameters was seen for either gene polymorphism, except that men had a somewhat higher frequency than women of the APE1 Asp/Asp genotype ($P = 0.049$). Direct sequencing analysis showed that 97 of 217 (44.7%) lung tumor samples had p53 mutations. The frequencies of p53 mutation in men, smokers, and in squamous cell carcinomas were significantly higher than in women ($P = 0.003$), nonsmokers ($P = 0.004$), and adenocarcinomas ($P = 0.001$; Table 2), respectively. In addition, the frequency of p53 mutation was higher in participants with late-stage tumors (II and III) than in those with early-stage tumors (I) (57% for stage II, 49% for stage III vs 34% for stage I).

We therefore examined whether p53 mutation was more frequent in participants with high-risk genotypes of hOGG1 and APE1 than in those with low-risk genotypes. p53 mutation in lung tumors of this study population was not associated with hOGG1 polymorphisms. However, participants with the APE1 Asp/Asp genotype had an OR of 2.15 (95% CI, 1.19–3.87; $P = 0.011$) for the risk of p53 mutation as compared with those with the APE1 Asp/Glu + Glu/Glu genotype after adjusting for covariates, including sex, smoking status, and tumor histology and stage (Table 3).

We next examined the combined effects of hOGG1 and APE1 on p53 mutation in lung tumors after adjustment for covariates such as sex, smoking status, and tumor histology and stage. Participants with the Ser/Cys + Cys/Cys plus Asp/Asp had an OR of 3.72 (95% CI, 1.33–10.40; $P = 0.012$) for p53 mutation as compared with participants with the Ser/Ser plus Asp/Glu + Glu/Glu (Table 3).

**Direct sequencing of the p53 gene**

To identify mutations in exons 5–8 of the p53 gene, an autosequencer (ABI 3100-Avant Genetic Analyzer; Applied Biosystems, Foster City, CA, USA) was used for direct sequencing of PCR products amplified from lung tumor tissues as described previously.\textsuperscript{27,28}

**Methods**

**Participants**

From 1993 to 2005, surgical specimens were obtained from 217 patients at Taichung Veterans General Hospital, Taichung, Taiwan, ROC who had histologically or cytologically confirmed primary non–small cell lung cancer (NSCLC). All participants were older than 18 years and had incident primary lung cancer. Age ranged from 38 to 84 years. Written informed consent for the use of tumor specimens was obtained from each participant before surgery, as required by the Institutional Review Board at Taichung Veteran’s General Hospital. Demographic data for each individual, including age, sex, tumor type and stage, and smoking status, were collected by interview and a review of hospital charts. Smokers were defined as current or previous smokers, and nonsmokers were defined as individuals who had never smoked.

**Genotyping of the hOGG1 and APE1 polymorphisms**

Genotyping analysis of the hOGG1 Ser326Cys (C1245G) and APE1 Asp148Glu (T1350G) polymorphism from genomic DNA samples of adjacent normal lung tissue was conducted by PCR-RFLP as described previously.\textsuperscript{17,21}
combined effects of polymorphisms in both genes on p53 mutation were not evident in other combinations, including Ser/Cys + Cys/Cys plus Asp/Glu + Glu/Glu and Ser/Ser plus Asp/Asp (Table 3). Although differences in participants with the Ser/Ser plus Asp/Asp were not statistically significant, the OR for p53 mutation was 3.29 (95% CI, 0.94–11.51;  \textit{P} = 0.062; Table 3). The lack of statistical significance could have been the result of the lower number of participants in this subgroup.

**Effects of hOGG1 and APE1 polymorphisms on p53 mutation according to smoking status and tumor histology**

Participants were stratified by sex, smoking status, and tumor histology to determine whether hOGG1 and APE1 polymorphisms had differing effects on p53 mutation. The hOGG1 polymorphism was not associated with p53 mutation in the 6 subgroups (Table 4). However, as shown in Table 5, the APE1 polymorphism was associated with p53 mutation in nonsmokers (OR, 3.45; 95% CI, 1.39–8.53;  \textit{P} = 0.007) and in squamous cell carcinoma samples (3.21; 1.38–7.47,  \textit{P} = 0.007). The association of APE1 polymorphism with the risk of p53 mutation was marginal in both women and men (Table 5). The OR for p53 mutation associated with APE1 polymorphism combined with hOGG1 polymorphism markedly increased, from 3.45 to 6.78 and from 3.21 to 8.11, in nonsmokers and squamous cell carcinoma, respectively (Table 6). However, combined effects of hOGG1 and APE1 polymorphisms on the risk of p53 mutation were not seen in participants with adenocarcinoma (Table 6).

### Table 1. Associations between clinical parameters and genotypes

| Characteristics          | NOGG1 Ser/Ser | NOGG1 Ser/Cys + Cys/Cys | \( P \)  | APE1 Asp/Asp | APE1 Asp/Glu + Glu/Glu | \( P \)  |
|--------------------------|---------------|-------------------------|--------|-------------|------------------------|--------|
| Age, y <66               | 108           | 80 (74)                 | 0.608  | 42 (39)     | 66 (61)                | 0.298  |
| Age, y ≥66               | 109           | 84 (77)                 | 0.500  | 50 (46)     | 59 (54)                |        |
| Sex Female               | 65            | 51 (78)                 | 0.518  | 21 (32)     | 44 (68)                | 0.049  |
| Sex Male                 | 152           | 113 (74)                | 0.747  | 71 (47)     | 81 (53)                |        |
| Smoking status Nonsmoker | 104           | 78 (75)                 | 0.850  | 40 (38)     | 64 (62)                | 0.260  |
| Smoking status Smoker    | 113           | 86 (76)                 | 0.526  | 52 (46)     | 61 (54)                |        |
| Tumor histology Adenocarcinoma | 111   | 83 (75)                 | 0.779  | 48 (43)     | 63 (57)                | 0.796  |
| Tumor histology Squamous carcinoma | 106  | 81 (76)                 | 0.642  | 44 (42)     | 62 (58)                |        |
| Stage I                  | 80            | 62 (77)                 | 0.358  | 37 (46)     | 43 (54)                | 0.624  |
| Stage II                 | 35            | 29 (83)                 | 1.37   | 13 (37)     | 22 (63)                |        |
| Stage III                | 102           | 73 (72)                 | 1.08   | 42 (41)     | 60 (59)                |        |

**P** values obtained from the chi-square test.

### Table 2. Association of p53 mutation with clinical characteristics of patients with lung cancer

| Characteristics          | No. (%) | OR (95% CI) | \( P \)  |
|--------------------------|---------|-------------|--------|
| Age, y <66               | 108 (56) | 48 (44)     | 1 0.940 |
| Age, y ≥66               | 109 (55) | 49 (45)     | 1.02 (0.59–1.74) |
| Sex Female               | 65 (71) | 19 (29)     | 1 0.003 |
| Sex Male                 | 152 (49) | 78 (51)     | 2.55 (1.37–4.15) |
| Smoking status Nonsmoker | 104 (65) | 36 (35)     | 1 0.004 |
| Smoking status Smoker    | 113 (52) | 61 (54)     | 2.22 (1.28–3.83) |
| Tumor histology Adenocarcinoma | 111 | 37 (33)     | 1 0.001 |
| Tumor histology Squamous cell carcinoma | 106 | 60 (57)     | 2.61 (1.50–4.53) |
| Stage I                  | 80 (53) | 27 (34)     | 1 0.021 |
| Stage II                 | 35 (52) | 20 (57)     | 2.62 (1.16–5.91) |
| Stage III                | 102 (52) | 50 (49)     | 1.89 (1.03–3.46) |

### Table 3. Combined effects of hOGG1 and APE1 polymorphisms on p53 mutation in patients with lung cancer

| Genes                  | No. (%) | OR (95% CI) | \( P \)  |
|------------------------|---------|-------------|--------|
| hOGG1                  | 53 (22) | 0.97 (0.35–2.72) | 0.953 |
| APE1                   | 90 (50) | 1.99 (0.89–5.76) | 0.200 |
| hOGG1 and APE1         | 27 (8)  | 2.08 (0.77–5.61) | 0.148 |
| Nonsmokers             | 98 (39) | 3.29 (0.94–11.51) | 0.062 |
| Smokers                | 126 (47) | 2.15 (1.19–3.87) | 0.011 |

\*Adjusted for sex, smoking status, and tumor histology and stage.

### Table 4. Effect of hOGG1 polymorphism on p53 mutation in patients with lung cancer, according to sex, smoking status, and tumor histology

| Genes                  | No. (%) | OR (95% CI) | \( P \)  |
|------------------------|---------|-------------|--------|
| Women Ser/Ser          | 14 (3)  | 1 0.655  |
| Women Ser/Cys + Cys/Cys| 51 (16) | 1.39 (0.33–5.96) |
| Men Ser/Ser            | 39 (9)  | 1 0.550  |
| Men Ser/Cys + Cys/Cys  | 113 (59) | 1.26 (0.59–2.70) |
| Nonsmokers             | 26 (9)  | 1 0.954  |
| Nonsmokers Ser/Cys + Cys/Cys | 78 (27) | 1.03 (0.39–2.72) |
| Smokers Ser/Ser        | 27 (13) | 1 0.364  |
| Smokers Ser/Cys + Cys/Cys | 86 (48) | 1.52 (0.62–3.76) |
| Squamous cell carcinoma | 83 (6)  | 1.41 (0.44–4.50) |
| Ser/Ser                | 25 (11) | 1 0.117  |
| Ser/Cys + Cys/Cys      | 81 (49) | 2.10 (0.38–5.30) |

\*Adjusted for smoking status and tumor histology and stage.

\*Adjusted for sex and tumor histology and stage.

\*Adjusted for sex, smoking status, and tumor stage.
DISCUSSION

In this study, the prevalence of hOGG1 Cys/Cys was 26.7% (58 of 217) in Taiwanese with lung cancer. The distribution of hOGG1 Cys/Cys in this population was lower than in previous studies of Taiwanese with lung cancer (39.8% and 36.9%). The prevalence of hOGG1 Cys/Cys in Japanese and Chinese adults with lung cancer ranged from 17.0% to 27.4% and from 16.9% to 36.1%, respectively. Interestingly, the prevalence of hOGG1 Cys/Cys in whites with lung cancer ranged from 2.7% to 18.2%, which is significantly lower than in Taiwanese, Japanese, and Chinese patient populations.

The prevalence of the hOGG1 Cys/Cys genotype in this population was not higher than in other studies of Asian populations (eTable 2).

Substantial evidence indicates that hOGG1 Ser326Cys is associated with an increased risk of lung cancer.16–20 An early in vitro study provided cellular evidence that, as compared with the hOGG1 Ser/Ser genotype, the hOGG1-Cys variant results in less repair of 8-hydroxyguanine in damaged DNA.29 A more recent study confirmed this finding and also noted that the hOGG1-Cys variant resulted in less DNA glycosylase activity as compared with the hOGG1-Ser/Ser genotype. However, a biological function of hOGG1 Ser326Cys polymorphism was not supported, as the hOGG1-Cys variant was not associated with p53 mutation in patients with lung cancer.30 This discrepancy may have been due to the predominant influence of APE1 on the DNA glycosylase activity of hOGG1. In the present study, we consistently found that the hOGG1 Ser326Cys polymorphism was not associated with p53 mutation in patients with lung cancer.30 This finding lends support to the hypothesis that hOGG1 activity in the repair of oxidative damage to DNA is strongly regulated by APE1.

Findings regarding an association between the APE1 Asp148Glu polymorphism and lung cancer risk have been inconsistent. A recent study showed that lung cancer risk was higher for the APE1-Glu variant than for the APE1-Asp/Asp genotype,24 whereas other studies found no association between APE1 polymorphism and lung cancer risk.16,21–23 Another report found that lung cancer was lower for the APE1-Glu variant than for the APE1-Asp/Asp genotype, especially in smokers.31 In addition, individuals with advanced NSCLC who had the APE1-Glu variant had poorer responses to chemotherapy and radiotherapy than did those with the APE1-Asp/Asp genotype.22 An in vitro biochemical study found that endonuclease activity and DNA binding activity were unaffected by APE1 Asp148Glu polymorphism.15

In the present study, APE1 polymorphism was associated with p53 mutation in patients with squamous cell carcinoma, which is more common among smokers. However, an association between APE1 polymorphism and p53 mutation was seen only in nonsmokers (Table 5). Among nonsmokers, 8 of 10 Asp/Asp (80%) carriers versus 5 of 16 Asp/Glu + Glu/Glu (31%) carriers with p53 mutation had squamous cell carcinoma; however, 12 of 30 Asp/Asp carriers (40%) versus 11 of 48 Asp/Glu + Glu/Glu (23%) with p53 mutation had adenocarcinoma. Therefore, the association of APE1 polymorphism with p53 mutation in nonsmokers was higher among those with squamous cell carcinoma than in those with adenocarcinoma.

Combined APE1 and hOGG1 polymorphism markedly increased the risk of p53 mutation in nonsmokers and patients.
with squamous cell carcinoma (Table 6). However, combined polymorphism did not increase the risk of p53 mutation in patients with adenocarcinoma (Table 6). This could be due to the lower rate of p53 mutation in patients with adenocarcinoma as compared with squamous cell carcinoma patients (33% vs 57%, P = 0.001; Table 2). These results suggest that the effects of hOGG1 and APE1 polymorphism on the risk of p53 mutation differ according to smoking status and tumor histology. However, these findings should be verified in a larger study population.

In summary, the risk of p53 mutation was higher among Taiwanese lung cancer patients with the APE1 Asp/Asp genotype than in those with the APE1-Glu variant. In addition, participants with the APE1 Asp/Asp genotype combined with hOGG1-Cys variant had the highest risk of p53 mutation.

ACKNOWLEDGMENTS

This work was supported by grants from the Department of Health (DOH 96-TD-G-111-006) and National Science Council (NSC-96-2628-B-040-002-MY3), The Executive Yuan, ROC.

Conflicts of interest: None declared.

ONLINE ONLY MATERIALS

eTables are available on the journal’s website at http://dx.doi.org/10.2188/jea.JE20120048.

REFERENCES

1. Department of Health, Executive Yuan, Taiwan, Republic of China. Health and Vital Statistics, Vol II. Vital Statistics. Taipei, Taiwan: Executive Yuan, Taiwan, Republic of China; 2004.

2. Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol. 2000;18:2309–15.

3. Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene. 2002;21:6870–6.

4. Gackowski D, Kowalewski J, Siomek A, Ołinski R. Oxidative DNA damage and antioxidant vitamin level: comparison among lung cancer patients, healthy smokers and nonsmokers. Int J Cancer. 2005;114:153–6.

5. Thaiparambil JT, Vadhanam MV, Srinivasan C, Gairola CG, Gupta RC. Time-dependent formation of 8-oxo-deoxyguanosine in the lungs of mice exposed to cigarette smoke. Chem Res Toxicol. 2007;20:1737–40.

6. Tudek B. Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med. 2007;28:258–75.

7. Orlow I, Park BJ, Mujumdar U, Patel H, Sin-Lau P, Clas BA, et al. DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. J Clin Oncol. 2008;26:3560–6.

8. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5:811–5.

9. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8:605–15.

10. Vidal AE, Hickson ID, Boiteux S, Radicella JP. Mechanism of stimulation of the DNA glycosylase activity of hOGG1 by the major human AP endonuclease: bypass of the AP lyase activity step. Nucleic Acids Res. 2001;29:1285–92.

11. David SS, O’Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. Nature. 2007;447:941–50.

12. Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 2008;18:27–47.

13. Smart DJ, Chipman JK, Hodges NJ. Activity of OGG1 variants in the repair of pro-oxidant-induced 8-oxo-2′-deoxyguanosine. DNA Repair (Amst). 2006;5:1337–45.

14. Bravard A, Vacher M, Moritz E, Vasil L, Hall J, Epe B, et al. Oxidation status of human OGG1–S326C polymorphic variant determines cellular DNA repair capacity. Cancer Res. 2009;69:3642–9.

15. Hadi MZ, Coleman MA, Fidelis K, Mohrenweiser HW, Wilson DM. 3rd. Functional characterization of Ape1 variants identified in the human population. Nucleic Acids Res. 2000;28:3871–9.

16. Le Marchand L, Donlon T, Lum-Jones A, Seifried A, Wilkens LR. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:409–12.

17. Park J, Chen L, Tockman MS, Elahi A, Lazarus P. The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. Pharmacogenetics. 2004;14:103–9.

18. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol. 2005;162:925–42.

19. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006;27:560–7.

20. Chang CH, Hsiao CF, Chang GC, Tsai YH, Chen YM, Huang MS, et al. Interactive effect of cigarette smoking with human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) polymorphisms on the risk of lung cancer: a case-control study in Taiwan. Am J Epidemiol. 2009;170:695–702.

21. Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiuira T, Saito T, et al. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis. 2004;25:1395–401.

22. Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2004;25:1395–401.

23. Lo YL, Jou YS, Hsiao CF, Chang GC, Tsai YH, Su WC, et al. A combination of DNA repair gene polymorphisms and smoking interacts with the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:223–9.

24. De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, et al. Interactive effect of cigarette smoking with human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) polymorphisms on the risk of lung cancer: a case-control study in Taiwan. Am J Epidemiol. 2009;170:695–702.
Claes K, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res. 2007;631:101–10.

25. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21:7435–51.

26. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanière P, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005;65:5076–83.

27. Chien WP, Wong RH, Wu TC, Cheng YW, Chen CY, Lee H. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer. Ann Surg Oncol. 2009;16:1918–24.

28. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res. 2007;67:10686–93.

29. Kohno T, Shinmura K, Tosaka M, Tani M, Kim SR, Sugimura H, et al. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene. 1998;16:3219–25.

30. Hu YC, Ahrendt SA. hOGG1 Ser326Cys polymorphism and G:C-to-T:A mutations: no evidence for a role in tobacco-related non small cell lung cancer. Int J Cancer. 2005;114:387–93.

31. Deng Q, Sheng L, Su D, Zhang L, Liu P, Lu K, et al. Genetic polymorphisms in ATM, ERCC1, APE1 and iASPP genes and lung cancer risk in a population of southeast China. Med Oncol. 2011;28:667–72.

32. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56:281–8.